Frontiers in Molecular Neuroscience (May 2023)

The month of walking alone and BDNF level differ between drug-naive first-episode schizophrenia patients and healthy controls

  • Zhenmei Zhang,
  • Lejia Fan,
  • Liu Yuan,
  • Zongchang Li,
  • Lijun Ouyang,
  • Xiaoqian Ma,
  • Zihao Yang,
  • Jingyan Lv,
  • Shuting Chen,
  • Xiaogang Chen,
  • Xiaogang Chen,
  • Ying He,
  • Ying He

DOI
https://doi.org/10.3389/fnmol.2023.1177524
Journal volume & issue
Vol. 16

Abstract

Read online

IntroductionSchizophrenia is a neurodevelopmental disorder, characterized by impairment in reasoning, affectivity, and social relationships. Previous studies have shown delayed motor development and Brain-Derived Neurotrophic Factor (BDNF) level change in individuals with schizophrenia. We researched the month of walking alone (MWA) and BDNF level between drug-naive first-episode schizophrenia patients (FEP) and healthy control (HC), as well as how they behave in neurocognitive function and severity of symptoms. Predictors of schizophrenia were further explored too.MethodsWe researched the MWA and BDNF levels between FEP and HCs in the Second Xiangya Hospital of Central South University from August 2017 to January 2020, as well as how they behave in neurocognitive function and the severity of symptoms. A binary logistic regression analysis was used to examine the risk factors affecting the onset and treatment outcome of schizophrenia.ResultsWe find that FEP showed a walking delay and lower BDNF levels compared to HCs, which were associated with cognitive impairment and severity of symptoms. According to the difference and correlation analysis results, and combined with the appropriate application conditions for binary logistic regression, Wechsler Intelligence Scale Picture completion, Hopkins Verbal Learning Test-Revised, and Trail Making Test: part A were added to the binary logistic regression analysis to distinguish FEP and HCs.ConclusionOur study has shown delayed motor development and changes in BDNF levels in schizophrenia, extending insight into the early identification of patients with schizophrenia versus healthy populations.

Keywords